When was Structure founded?

Structure was founded in 2017 and raised its 1st funding round 4 years after it was founded.

Where is Structure located?

Structure is headquartered in San Francisco, United States.

How many employees does Structure have?

As of Aug 31, 2026, the latest employee count at Structure is 256.

Is Structure a funded company?

Structure is a funded company, having raised a total of $191M across 2 funding rounds to date. The company's 1st funding round was a $***** Series B round, raised on Oct 20, 2021.

When was the latest funding round of Structure?

Structure's latest funding was a $***** Series B round on Aug 01, 2022, with participation from 2 investors.

Where does Structure rank among its competitors?

Structure ranks 13th amongst 779 active competitors, of which 247 are funded. It stands 3rd in terms of total funding among its competitors. The most recent competitor to raise funding was Sana Biotechnology, which secured $25M in Aug, 2026.

Who are the top competitors of Structure?

Structure's top competitors include argenx, Sana Biotechnology and Rhythm Pharmaceuticals. Among them, Sana Biotechnology secured the most recent funding round in August, 2026.

Structure - 2026 Company Profile, Team, Funding, Competitors & Financials

Structure is a public company based in San Francisco (United States), founded in 2017. It operates as a Developer of oral small molecule drugs for chronic diseases. Structure has raised $191M in funding from BVF Partners. The company has 779 active competitors, including 247 funded and 196 that have exited. Its top competitors include companies like argenx, Sana Biotechnology and Rhythm Pharmaceuticals.

Company Details

Developer of oral small molecule drugs for chronic diseases. It offers GPCR structure-based biologic and peptide drugs for pulmonary hypertension, pulmonary fibrosis, type 2 diabetes, and obesity. It has a structure-based technology platform that combines receptor-binding interactions with the simulation of molecular motion and signal transduction for drug development.

Website: structuretx.com
Social
Email ID: *****@shoutipharma.com

Key Metrics

Founded Year

2017

Location

San Francisco, United States

Stage

Public

Total Funding

$191M in 2 rounds

Latest Funding Round

Series B, Aug 01, 2022, $*****

Investors

BVF Partners & 18 more

Ranked

13^th among 779 active competitors

Employee Count

256 as on Aug 31, 2026

Similar Companies

Sana Biotechnology & 762 more

Exit Details

Public

View Structure's full profile

Structure is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
Structure Therapeutics Inc. CIN: 981480821 , United States, Active	Dec 31, 2016	-	93 (As on Dec 31, 2023)	-

Structure got listed on Feb 03, 2023.

Click here to take a look at Structure's IPO in detail

Structure has raised a total funding of $191M over 2 rounds. Its first funding round was on Oct 20, 2021. Its latest funding round was a Series B round on Aug 01, 2022 for $*****. 2 investors participated in its latest round. Structure has 19 institutional investors.

Here is the list of recent funding rounds of Structure:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Aug 01, 2022	6911755	Series B	6685417	5892348	1285345	7422878
Oct 20, 2021	5449878	Series B	7822289	9920145	BVF Partners	Casdin Capital & 15 more

Access funding benchmarks and valuations. Sign up today!

View details of Structure's funding rounds and investors

Structure's employee count trend

Structure has 256 employees as of Aug 26. Here is Structure's employee count trend over the years:

Uncover Structure's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Structure include argenx, Sana Biotechnology and Rhythm Pharmaceuticals. Here is the list of Top 10 competitors of Structure, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	argenx 2008, Ghent (Belgium), Public	Developer of antibody-based drugs to treat autoimmune diseases and cancer	$61.9M	Life Sciences Partners, Seventure Partners ... & 21 others	75/100
2nd	Sana Biotechnology 2018, Seattle (United States), Public	Developer of engineered cell therapies for treating various human diseases	$821M	Baillie Gifford, PSP Investments & 18 others	74/100
3rd	Rhythm Pharmaceuticals 2010, Boston (United States), Public	Developer of peptide therapeutics for the treatment of rare genetic deficiencies	$84M	Pfizer Venture Investments, Third Rock Ventures ... & 9 others	70/100
4th	Tenaya Therapeutics 2016, San Francisco (United States), Public	Developer of regenerative and gene therapeutics for heart failure	$248M	RTW Investments, Fidelity Investments & 7 others	70/100
5th	MannKind Corp 1991, Los Angeles (United States), Public	Developer of small-molecule drugs	$50M	Colt Ventures, Ignite 500 & 1 others	70/100
6th	Adocia 2005, Lyon (France), Public	Developer of therapeutics for the treatment of diabetes and obesity	$26M	Stifel, Smalt Capital & 6 others	69/100
7th	Corcept 1998, Menlo Park (United States), Public	Developer of cortisol modulators for the treatment of various diseases	-	Longitude Capital, BioBrit & 7 others	68/100
8th	Vor Biopharma 2019, Cambridge (United States), Public	Developer of therapeutics to treat acute myeloid leukemia	$152M	NEXTBio, Mingxin Capital & 10 others	68/100
9th	Ventyx Biosciences 2018, Encinitas (United States), Acquired	Developer of therapeutics to treat autoimmune diseases	$165M	VenBio, Logos Capital & 13 others	66/100
10th	Esperion Therapeutics 1998, Ann Arbor (United States), Acquired	Developer of lipoprotein cholesterol (LDL-C) lowering therapies	$107M	Alta Partners, Longitude Capital & 16 others	66/100
13th	Structure 2017, San Francisco (United States), Public	Developer of oral small molecule drugs for chronic diseases	$191M	BVF Partners, Janus Henderson Investors & 17 others	65/100